(Q37690442)

22 August 2017

1 reference

title

Telmisartan: a different angiotensin II receptor blocker protecting a different population? (English)

1 reference

22 August 2017

M Burnier

1

1 reference

22 August 2017

publication date

1 November 2009

1 reference

Journal of International Medical Research

22 August 2017

published in

1 reference

22 August 2017

volume

37

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

1662-1679

1 reference

Telmisartan, ramipril, or both in patients at high risk for vascular events

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Atherosclerosis is an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Inflammation and angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

C-reactive protein (CRP)-lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Lipids and glucose in type 2 diabetes: what is the cause and effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effect of telmisartan on cholesterol levels in patients with hypertension - Saga Telmisartan Aggressive Research (STAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

T cells in arteritis and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

The role of nitric oxide in the regulation of glomerular haemodynamics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Sustained antihypertensive activity of telmisartan compared with valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Left ventricular hypertrophy as a risk factor in arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Is angiotensin II a proliferative factor of cardiac fibroblasts?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Connective tissue and the heart. Functional significance and regulatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000903700602

10.1177/147323000903700602

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference